MedTrace Logo

Pattern Separation in Major Depressive Disorder

NCT07139834 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-03

No results posted yet for this study

Summary

This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functional magnetic resonance imaging, and depressive symptoms, in participants with Major Depressive Disorder. Escitalopram is administered in an open-label fashion in this study; extended release memantine is administered in a double-blind, randomized, placebo-controlled manner.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DRUG

SSRI (escitalopram or sertraline)

11 weeks of open-label treatment with an SSRI, of which the last 6 weeks are augmented with memantine vs placebo. Primary SSRI for the study is escitalopram. In cases of prior intolerance or non-response to escitalopram, individuals will be treated with sertraline instead of escitalopram.

DRUG

Extended-Release Memantine

6 weeks of treatment with extended-release memantine as augmentation to ongoing escitalopram treatment

DRUG

Placebo

6 weeks of treatment with placebo as augmentation to ongoing escitalopram treatment

Sponsors & Collaborators

  • Jeffrey Miller

    lead OTHER

Principal Investigators

  • Jeffrey M Miller, MD · New York State Psychiatric Institute (NYSPI)

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2028-08-31
Completion
2028-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07139834 on ClinicalTrials.gov